Xi Venture Capital was awarded the TOP20 Best Investment Institutions in Biopharmaceuticals for the year 2023

　　On May 15th, the "2023 China Medical and Health Industry Investment and Financing Honor List" series of rankings was officially announced. Xi Venture Capital was awarded the "Top 20 Best Investment Institutions in Biopharmaceuticals in 2023", and Fu Haiying, the Managing Director of the company's biopharmaceutical team, was awarded the "Annual Medical and Health Honor Star". Xi Venture Capital's invested companies, such as Xiantong Pharmaceutical, Saina Biotechnology, and Kemeixin, were listed.

　　Xichuang Capital Biopharmaceuticals currently invests in innovative drugs, biotechnology, medical devices, synthetic biology, and other fields. It has invested in companies such as Ruiyue Biotechnology, Xiantong Pharmaceutical, Jianshi Medical, Kemeixin, Heqirui, Yituo Pharmaceutical, Xianlin 3D, and the privatization of Fansheng US stocks, all of which have international leading technological advantages in their respective sub fields. The company relies on the advantages of Wuxi's biopharmaceutical industry, adheres to the path of marketization and specialization, and has established a top-down investment research system. It has won multiple equity investment industry honors such as the "Top 20 China Medical and Health Industry Investment Funds" award, the "Best Innovative Pharmaceutical Investment Institution of the Year" and "Best Early Investment Institution of the Year in Medical and Health" award on the Zhuoyue List, and the "Annual Medical and Health Strategic Investment Institution of the Year" award for Future Medical in 2024. Future Xi Venture Capital will continue to forge ahead and explore and invest in more valuable enterprises.